|
| dbGaP Submitter Subject ID (ID2) | Coriell Sample ID | Consent | Control | Gender | Race | Age | Baseline Max AMD Severity | Final Max AMD Severity |
| AR2_0786 | ED148325 | General Research Use | No | Female | White | 71 | 5 - AREDS AMD Severity Scale Step 5 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_0860 | ED150031 | General Research Use | No | Female | White | 77 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_1300 | ED149098 | General Research Use | No | Female | White | 81 | 5 - AREDS AMD Severity Scale Step 4 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_1701 | ED149579 | General Research Use | No | Female | White | 70 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_1866 | ED148692 | General Research Use | No | Female | White | 69 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2003 | ED148048 | General Research Use | No | Female | White | 75 | 5 - AREDS AMD Severity Scale Step 5 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_2091 | ED148421 | General Research Use | No | Female | White | 74 | 5 - AREDS AMD Severity Scale Step 4 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_2731 | ED149788 | General Research Use | No | Male | White | 64 | 5 - AREDS AMD Severity Scale Step 4 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2962 | ED148724 | General Research Use | No | Female | White | 64 | 5 - AREDS AMD Severity Scale Step 5 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0829 | ED150010 | General Research Use | No | Male | White | 75 | 5 - AREDS AMD Severity Scale Step 5 | 8 - AREDS AMD Severity Scale Step 8 |
| AR2_1357 | ED150008 | General Research Use | No | Female | White | 51 | 5 - AREDS AMD Severity Scale Step 5 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_0306 | ED149545 | General Research Use | No | Male | White | 77 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_0363 | ED148374 | General Research Use | No | Male | White | 57 | 5 - AREDS AMD Severity Scale Step 5 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_0397 | ED149753 | General Research Use | No | Female | White | 74 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_2038 | ED149945 | General Research Use | No | Male | Black or African American | 64 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_3446 | ED149199 | General Research Use | No | Female | White | 84 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_1328 | ED149468 | General Research Use | No | Female | White | 58 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_1361 | ED148167 | General Research Use | No | Female | White | 73 | 5 - AREDS AMD Severity Scale Step 5 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_1750 | ED148986 | General Research Use | No | Female | White | 77 | 5 - AREDS AMD Severity Scale Step 3 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2653 | ED149218 | General Research Use | No | Female | White | 72 | 5 - AREDS AMD Severity Scale Step 5 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |